Camptosar is a brand name of irinotecan, approved by the FDA in the following formulation(s):
CAMPTOSAR (irinotecan hydrochloride - injectable; injection)
Manufacturer: PFIZER INC
Approval date: June 14, 1996
Strength(s): 100MG/5ML (20MG/ML) [RLD][AP], 40MG/2ML (20MG/ML) [RLD][AP]
Manufacturer: PFIZER INC
Approval date: August 5, 2010
Strength(s): 300MG/15ML (20MG/ML) [RLD]
Has a generic version of Camptosar been approved?
A generic version of Camptosar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Camptosar and have been approved by the FDA:
irinotecan hydrochloride injectable; injection
Manufacturer: ACCORD HLTHCARE
Approval date: November 21, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: ACTAVIS TOTOWA
Approval date: February 27, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: AKORN
Approval date: September 16, 2009
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: APP PHARMS
Approval date: February 27, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: BEDFORD LABS
Approval date: December 24, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: BIONICHE PHARMA
Approval date: May 13, 2011
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: DR REDDYS LABS LTD
Approval date: April 15, 2010
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: EBEWE PHARMA
Approval date: November 12, 2009
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: EMCURE PHARMS LTD
Approval date: February 14, 2012
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: FRESENIUS KABI ONCOL
Approval date: February 27, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: HIKMA FARMACEUTICA
Approval date: December 20, 2010
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: HOSPIRA
Approval date: February 27, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: JIANGSU HENGRUI MED
Approval date: December 16, 2011
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: PLIVA LACHEMA
Approval date: October 31, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: SUN PHARMA GLOBAL
Approval date: April 21, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: TEVA PARENTERAL
Approval date: February 27, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: WATSON LABS
Approval date: February 20, 2008
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Manufacturer: X-GEN PHARMS
Approval date: January 28, 2009
Strength(s): 100MG/5ML (20MG/ML) [AP], 40MG/2ML (20MG/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Camptosar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Patent 6,403,569
Issued: June 11, 2002
Inventor(s): Wolf R.; Achterrath
Assignee(s): Aventis Pharma S.A.
A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.Patent expiration dates:
- April 28, 2020✓
- October 28, 2020✓
- April 28, 2020
Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Patent 6,794,370
Issued: September 21, 2004
Inventor(s): Wolf R.; Achterrath
Assignee(s): Aventis Pharma S.A.
A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.Patent expiration dates:
- May 1, 2020✓
- November 1, 2020✓
- May 1, 2020
See also...
- Camptosar Consumer Information (Drugs.com)
- Camptosar Consumer Information (Wolters Kluwer)
- Camptosar Consumer Information (Cerner Multum)
- Camptosar Advanced Consumer Information (Micromedex)
- Camptosar AHFS DI Monographs (ASHP)
- Irinotecan Consumer Information (Wolters Kluwer)
- Irinotecan Consumer Information (Cerner Multum)
- Novaplus Irinotecan Hydrochloride Advanced Consumer Information (Micromedex)
- Irinotecan Intravenous Advanced Consumer Information (Micromedex)
- Irinotecan Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment